William Blair Comments on Charles River Laboratories International, Inc.’s Q1 2025 Earnings (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair reduced their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a note issued to investors on Thursday, August 8th. William Blair analyst M. Smock now anticipates that the medical research company will earn $2.53 per share for the quarter, down from their prior forecast of $2.69. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.99 per share. William Blair also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.74 EPS.

A number of other brokerages have also recently commented on CRL. UBS Group lowered their target price on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. TD Cowen lowered their target price on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a report on Monday. Mizuho began coverage on Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price on the stock. Robert W. Baird cut Charles River Laboratories International from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $239.00 to $191.00 in a report on Thursday, August 8th. Finally, Evercore ISI lowered their target price on Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Ten analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $231.00.

Charles River Laboratories International Stock Performance

CRL opened at $203.49 on Monday. The stock’s 50 day simple moving average is $214.58 and its 200 day simple moving average is $231.16. The stock has a market cap of $10.48 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.32 and a beta of 1.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the period. Headlands Technologies LLC purchased a new position in shares of Charles River Laboratories International in the 1st quarter worth $41,000. VisionPoint Advisory Group LLC raised its position in shares of Charles River Laboratories International by 45.1% in the 4th quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock worth $49,000 after buying an additional 65 shares during the period. Brown Brothers Harriman & Co. raised its position in shares of Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after buying an additional 193 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International declared that its board has approved a stock repurchase plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).